MK-0616 is a macrocyclic PCSK9 inhibitor with demonstrated once-daily PCSK9-lowering and LDL-cholesterol-lowering activities in a human clinical trial (<300 mg QD). Currently PCSK9-targeting therapies are only available by injection, and the cost-benefit of using large molecules to lower cholesterol has been hotly debated. Identification of [...]
1 minute read
Feb. 9, 2022
MK-0616: a Macrocyclic PCSK9 Inhibitor
Merck PCSK9 Inhibitors
macrocyclic PCSK9/LDLR PPI inhibitor oral PD in Ph. I with MK-0616 from mRNA display screen and SBDD published example: compound 44 Merck & Co.